Original Article
The Pharmacogenomics Journal (2008) 8, 122–128; doi:10.1038/sj.tpj.6500447; published online 27 March 2007
Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch
S P David1, M R Munafò2, M F G Murphy3, M Proctor4, R T Walton4,5 and E C Johnstone4
- 1Brown Medical School/Memorial Hospital of Rhode Island, Pawtucket, RI, USA
- 2Department of Experimental Psychology, University of Bristol, Bristol, UK
- 3Childhood Cancer Research Group, University of Oxford, Oxford, UK
- 4Department of Clinical Pharmacology, University of Oxford, Oxford, UK
- 5Medical Research Council Laboratories, Fajara, The Gambia
Correspondence: Dr SP David, Center for Primary Care and Prevention, Brown Medical School, 111 Brewster Street, Pawtucket, RI 02860, USA. E-mail: Sean_David@Brown.Edu
Received 13 July 2006; Revised 20 January 2007; Accepted 16 February 2007; Published online 27 March 2007.
Abstract
Smokers of European ancestry (n=720) who participated in a double-blind, randomised, placebo-controlled trial of transdermal nicotine replacement therapy, were genotyped for two functional polymorphisms (variable number of tandem repeats (VNTR) and a C to T transition at position –521 (C-521T)) in the dopamine D4 receptor gene (DRD4) gene. Logistic regression models of abstinence at 12- and 26-week follow-ups were carried out separately for each polymorphism. For the DRD4 VNTR models, the main effect of treatment was significant at both 12-week (P=0.001) and 26-week (P=0.006) follow-ups, indicating an increased likelihood of successful cessation on active nicotine replacement therapy transdermal patch relative to placebo. The main effect of DRD4 VNTR genotype was associated with abstinence at 12-week follow-up (P=0.034), with possession of one or more copies of the long allele associated with reduced likelihood of cessation (17 vs 23%), but this effect was not observed at 26-week follow-up. For the DRD4 C-521T models, no main effect or interaction terms involving genotype were retained in the models at either 12- or 26-week follow-up. These data are consistent with observations from studies of the DRD2 gene that genetic variants related to relatively decreased dopaminergic tone in the mesocorticolimbic system are associated with increased risk for relapse to smoking following a cessation attempt.
Keywords:
DRD4, VNTR, C-521T, smoking cessation, nicotine replacement therapy
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
Kidney International Original Article
Neuropsychopharmacology Original Article
Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR
The Pharmacogenomics Journal Original Article
Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment
The Pharmacogenomics Journal Original Article
